Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial

Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:22:28.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the response rate to Nivolumab preceded by epigenetic priming in a Phase II study of Epigenetic Therapy for Metastatic Non-Small Cell Lung Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:00.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail.
    Difference
    54%
    Check dated 2024-05-22T21:12:35.000Z thumbnail image
  8. Check
    41 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change represents an update in the estimated response rate to Nivolumab preceded by epigenetic priming in a Phase II study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab for subjects with Metastatic Non-Small Cell Lung Cancer.
    Difference
    0.1%
    Check dated 2024-05-06T17:56:09.000Z thumbnail image
  9. Check
    43 days ago
    Change Detected
    Summary
    The value '2023-06-07 Submitted' has recently changed to '2024-05-03 Posted' for Drug CC-486 300 143 in the webpage. This indicates that the results of the study have been submitted and posted, possibly related to medical and healthcare publications and documentation.
    Difference
    3%
    Check dated 2024-05-04T09:53:54.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:31:35.000Z thumbnail image

Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.